Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC – Get Rating) was the target of a significant drop in short-term interest in March. As of March 31, there was short interest totaling 2,110,000 shares, down 31.5% from the March 15 total of 3,080,000 shares. Based on an average daily trading volume of 842,200 shares, the day-to-cover ratio is currently 2.5 days. Approximately 8.7% of the company’s shares are sold short.
A number of equity analysts have commented on TRHC shares. StockNews.com upgraded Tabula Rasa HealthCare’s shares from a “sell” rating to a “hold” rating in a Saturday, April 2 research report. Robert W. Baird downgraded Tabula Rasa HealthCare from an “outperforming” rating to a “neutral” rating and lowered its target price for the stock from $24.00 to $11.00 in a Tuesday, February 1 report . Zacks Investment Research upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a target price of $6.25 for the company in a Tuesday, March 1 report. Benchmark lowered its target price on Tabula Rasa HealthCare from $30.00 to $15.00 and set a “buy” rating for the company in a Wednesday, March 2 report. Finally, SVB Leerink lowered its price target on Tabula Rasa HealthCare from $23.00 to $11.00 and set a “market performance” rating for the company in a Monday, February 28 report. Six research analysts gave the stock a hold rating and three gave the company’s stock a buy rating. Based on MarketBeat data, Tabula Rasa HealthCare currently has an average rating of “Hold” and an average price target of $14.53.
TRHC stock opened at $4.45 on Friday. The company has a market capitalization of $114.50 million, a PE ratio of -1.31 and a beta of 1.33. The company has a 50-day simple moving average of $5.99 and a 200-day simple moving average of $12.99. Tabula Rasa HealthCare has a 52-week minimum of $4.25 and a 52-week maximum of $53.38. The company has a quick ratio of 1.14, a current ratio of 1.22 and a debt ratio of 6.26.
Tabula Rasa HealthCare (NASDAQ:TRHC – Get Rating) last released its quarterly results on Thursday, February 24. The company reported ($0.09) EPS for the quarter, missing Zacks consensus estimate of ($0.08) by ($0.01). The company posted revenue of $85.69 million in the quarter, compared to analyst estimates of $85.19 million. Tabula Rasa HealthCare had a negative net margin of 23.86% and a negative return on equity of 61.87%. The company’s revenue for the quarter increased by 11.2% compared to the same quarter last year. During the same period last year, the company achieved EPS of ($0.53). On average, analysts expect Tabula Rasa HealthCare to post -1.35 EPS for the current fiscal year.
In related news, director Dennis Helling acquired 5,000 shares of Tabula Rasa HealthCare in a transaction on Friday, March 4. The shares were purchased at an average cost of $6.17 per share, with a total value of $30,850.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, director Gordon Tunstall acquired 10,000 shares of Tabula Rasa HealthCare in a transaction on Tuesday, March 1. The shares were purchased at an average cost of $5.50 per share, with a total value of $55,000.00. Disclosure of this purchase can be found here. Insiders bought 17,000 shares of the company valued at $97,110 over the past three months. 10.20% of the shares are held by insiders of the company.
Hedge funds have recently been buying and selling stocks. Vontobel Holding NV increased its stake in Tabula Rasa HealthCare by 50.3% in the third quarter. Vontobel Holding Ltd. now owns 81,927 shares of the company valued at $2,148,000 after purchasing an additional 27,405 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Tabula Rasa HealthCare in the third quarter, valued at approximately $635,000. Emerald Advisers LLC bought a new position in Tabula Rasa HealthCare in the fourth quarter worth approximately $72,000. Mattern Capital Management LLC increased its position in Tabula Rasa HealthCare by 44.4% in the fourth quarter. Mattern Capital Management LLC now owns 23,403 shares of the company valued at $351,000 after acquiring an additional 7,194 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY increased its position in Tabula Rasa HealthCare by 2.2% in the third quarter. Paradigm Capital Management Inc. NY now owns 78,900 shares of the company valued at $2,068,000 after acquiring an additional 1,700 shares in the last quarter. 88.29% of the shares are held by institutional investors and hedge funds.
Company Profile Tabula Rasa HealthCare (Get a rating)
Tabula Rasa HealthCare, Inc operates as a health technology company in the United States. The Company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication prescription and decision support platform for accessing patient medication information; and MedWise medication therapy management software, a cloud-based platform designed to make it easier to identify and resolve medication and health-related issues.
Get news and reviews for Tabula Rasa HealthCare Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com’s FREE daily newsletter.